Skip to main content
Erschienen in: hautnah dermatologie 1/2017

15.02.2017 | Dermatomyositis | Zertifizierte Fortbildung

Dermatomyositis

Malignomrisiko erfordert enges Monitoring

verfasst von: Prof. Dr. med. Michael Sticherling

Erschienen in: hautnah dermatologie | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapieoptionen der zur Gruppe der inflammatorischen Myopathien zählenden Dermatomyositis sind nach wie vor nicht zufriedenstellend. Dafür wurde in den letzten Jahren die Diagnostik verfeinert: Unter anderem ermöglichen neue Biomarker eine Verlaufsüberwachung oder eine Zuordnung zu Erkrankungsgruppen. Weiterhin bleibt aufgrund der Tumorassoziation eine engmaschige Überwachung notwendig.
Literatur
1.
Zurück zum Zitat Ekholm L et al. Autoantibody specificities and type I interferon pathway activation in Idiopathic Inflammatory Myopathies. Scand J Immunol 2016; 84: 100–9CrossRefPubMed Ekholm L et al. Autoantibody specificities and type I interferon pathway activation in Idiopathic Inflammatory Myopathies. Scand J Immunol 2016; 84: 100–9CrossRefPubMed
2.
Zurück zum Zitat Misunova M et al. Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activity. Clin Exp Rheumatol 2016; 34: 17–24PubMed Misunova M et al. Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activity. Clin Exp Rheumatol 2016; 34: 17–24PubMed
3.
Zurück zum Zitat Mammen AL et al. Myositisspecific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol Neuroimmunol Neuroinflamm 2015; 2(6): e172CrossRefPubMedPubMedCentral Mammen AL et al. Myositisspecific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol Neuroimmunol Neuroinflamm 2015; 2(6): e172CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Betteridge Z et al. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016; 280: 8–23CrossRefPubMed Betteridge Z et al. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016; 280: 8–23CrossRefPubMed
5.
Zurück zum Zitat Eichenfield DZ et al. Zebra Stripes in Dermatomyositis: Case Report and Review of Flagellate Erythema-Associated Dermatomyositis. J Eur Acad Dermatol Venereol 2017; 31: e7–9CrossRefPubMed Eichenfield DZ et al. Zebra Stripes in Dermatomyositis: Case Report and Review of Flagellate Erythema-Associated Dermatomyositis. J Eur Acad Dermatol Venereol 2017; 31: e7–9CrossRefPubMed
6.
Zurück zum Zitat Borghi A et al. Necrotic ulcerations in dermatomyositis: a marker of bad prognosis? G Ital Dermatol Venereol. 2016; 151: 318–9PubMed Borghi A et al. Necrotic ulcerations in dermatomyositis: a marker of bad prognosis? G Ital Dermatol Venereol. 2016; 151: 318–9PubMed
7.
Zurück zum Zitat Yu KH et al. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Medicine (Baltimore) 2016; 95: e3540CrossRef Yu KH et al. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Medicine (Baltimore) 2016; 95: e3540CrossRef
8.
Zurück zum Zitat Saini I et al. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int 2016; 36: 961–5CrossRefPubMed Saini I et al. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int 2016; 36: 961–5CrossRefPubMed
9.
Zurück zum Zitat Xu Y et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol 2016; 35: 113–6CrossRefPubMed Xu Y et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol 2016; 35: 113–6CrossRefPubMed
10.
Zurück zum Zitat Zhang L et al. Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. PLoS One 2016; 11: e0155381CrossRefPubMedPubMedCentral Zhang L et al. Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. PLoS One 2016; 11: e0155381CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Vuong V et al. Dermatomyositis: factors predicting relapse. J Eur Acad Dermatol Venereol 2016; 30: 813–8CrossRefPubMed Vuong V et al. Dermatomyositis: factors predicting relapse. J Eur Acad Dermatol Venereol 2016; 30: 813–8CrossRefPubMed
12.
Zurück zum Zitat Callander J et al. Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review. Br J Dermatol 2016; doi: 10.1111/bjd.14726 Callander J et al. Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review. Br J Dermatol 2016; doi: 10.1111/bjd.14726
13.
Zurück zum Zitat Kurtzman DJ et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol 2016; 152: 944–5CrossRefPubMed Kurtzman DJ et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol 2016; 152: 944–5CrossRefPubMed
14.
Zurück zum Zitat Dalakas MC et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000CrossRefPubMed Dalakas MC et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000CrossRefPubMed
15.
Zurück zum Zitat Habers GE et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatology (Oxford) 2016; 55: 1251–62CrossRef Habers GE et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatology (Oxford) 2016; 55: 1251–62CrossRef
16.
Zurück zum Zitat Del Barrio-Díaz P et al. Topical sodium metabisulfite for the treatment of calcinosis cutis: A promising new therapy. Br J Dermatol 2016; 175: 608–11CrossRefPubMed Del Barrio-Díaz P et al. Topical sodium metabisulfite for the treatment of calcinosis cutis: A promising new therapy. Br J Dermatol 2016; 175: 608–11CrossRefPubMed
17.
Zurück zum Zitat Bienvenu B. [Treatment of subcutaneous calcinosis in systemic disorders]. Rev Med Interne 2014; 35: 444–52CrossRefPubMed Bienvenu B. [Treatment of subcutaneous calcinosis in systemic disorders]. Rev Med Interne 2014; 35: 444–52CrossRefPubMed
Metadaten
Titel
Dermatomyositis
Malignomrisiko erfordert enges Monitoring
verfasst von
Prof. Dr. med. Michael Sticherling
Publikationsdatum
15.02.2017
Verlag
Springer Medizin
Schlagwort
Dermatomyositis
Erschienen in
hautnah dermatologie / Ausgabe Sonderheft 1/2017
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI
https://doi.org/10.1007/s15012-017-2308-y

Weitere Artikel der Sonderheft 1/2017

hautnah dermatologie 1/2017 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.